BCRX Stock - BioCryst Pharmaceuticals, Inc.
Unlock GoAI Insights for BCRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M |
| Gross Profit | $438.23M | $326.75M | $264.23M | $149.91M | $16.14M |
| Gross Margin | 97.2% | 98.6% | 97.6% | 95.4% | 90.6% |
| Operating Income | $-2,543,000 | $-103,709,000 | $-148,435,000 | $-177,720,000 | $-174,757,000 |
| Net Income | $-88,881,000 | $-226,539,000 | $-247,116,000 | $-184,062,000 | $-182,814,000 |
| Net Margin | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% |
| EPS | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Visit WebsiteEarnings History & Surprises
BCRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $0.05 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.07 | $0.06 | -14.3% | ✗ MISS |
Q3 2025 | Aug 4, 2025 | $0.03 | $0.15 | +400.0% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.07 | $0.00 | +100.2% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.07 | $-0.13 | -85.7% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2024 | Aug 5, 2024 | $-0.19 | $-0.06 | +68.4% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.25 | $-0.19 | +24.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $-0.19 | $-0.38 | -100.0% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | $-0.32 | $-0.23 | +28.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.39 | $-0.40 | -2.6% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.31 | $-0.40 | -29.0% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.30 | $-0.33 | -10.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Latest News
Frequently Asked Questions about BCRX
What is BCRX's current stock price?
What is the analyst price target for BCRX?
What sector is BioCryst Pharmaceuticals, Inc. in?
What is BCRX's market cap?
Does BCRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BCRX for comparison